Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations
Launched by UNIVERSITY OF READING · Nov 22, 2011
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this study is to determine how olive leaf is absorbed and metabolised and also whether it has any effect on vascular function and cytokine concentrations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 19-40 years, non-smokers, able to swallow capsules, have a Body Mass Index (BMI) of 18.5-30, have a normal liver function and haematology and a max alcohol intake of \<21 units/week
- Exclusion Criteria:
- • Those who suffer from any form of disease, including endocrine disease, liver disease, diabetes mellitus, myocardial infarction, blood clotting disorder, reproductive disorder, gastrointestinal disease or a chronic gastrointestinal disorder.
- • Individuals who are vegetarian, have dietary restrictions or on a weight reducing diet will not be recruited.
- • Subjects who have been taking antibiotics in previous 3 months before study will not be included in the study
- • Females who may be pregnant, or if of childbearing potential and are not using effective contraceptive precautions will be excluded.
- • Blood pressure \> 150/90 mmHg
- • Haemoglobin \< 125 g/l for male, \< 110 g/l for female
- • Gamma GT (liver enzymes) \> 80 IU/l
- • Cholesterol \> 6.5 mmol/l
- • Had suffered a myocardial infarction or stroke in the previous 12 months
- • On any lipid-modifying medication
- • On any medication affecting blood clotting
- • Individuals taking vitamin and/or fish oil supplements
About University Of Reading
The University of Reading is a prestigious research institution in the United Kingdom, renowned for its commitment to advancing knowledge across various disciplines, including health sciences. As a clinical trial sponsor, the university leverages its cutting-edge research facilities and interdisciplinary expertise to conduct innovative studies aimed at improving healthcare outcomes. With a strong emphasis on ethical research practices and collaboration with industry partners, the University of Reading strives to contribute valuable insights to the field of medicine, fostering the development of new treatments and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reading, Berkshire, United Kingdom
Patients applied
Trial Officials
Jeremy PE Spencer, PhD
Principal Investigator
University of Reading
Ian Rowland, PhD
Principal Investigator
University of Reading
Parveen Yaqoob, PhD
Principal Investigator
University of Reading
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials